I

Iovance Biotherapeutics
D

IOVA

8.54000
USD
0.30
(3.64%)
Market Closed
Volume
217,975
EPS
-1
Div Yield
-
P/E
-6
Market Cap
2,602,827,947
Related Instruments
    A
    ADPT
    -0.51000
    (-9.14%)
    5.07000 USD
    A
    ALLO
    -0.19000
    (-7.71%)
    2.27500 USD
    A
    ASTS
    -2.510
    (-9.37%)
    24.270 USD
    B
    BCEL
    0
    (0%)
    0.000000 USD
    C
    CRSP
    0.360
    (0.77%)
    47.280 USD
    F
    FATE
    -0.04500
    (-2.17%)
    2.02500 USD
    MRNA
    MRNA
    -2.950
    (-7.42%)
    36.830 USD
    S
    SLDB
    -0.45000
    (-8.46%)
    4.87000 USD
    More
News

Title: Iovance Biotherapeutics

Sector: Healthcare
Industry: Biotechnology
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.